欧美日本一道本一区二区_亚洲免费影视_91手机在线看片_精品欧美成人高清在线观看_少妇作爱bbbb免费看_51久久夜色精品国产水果派解说

新西蘭Living Cell Technologies (LCT)
Living Cell Technologies (LCT)是全球開發(fā)革命性活細(xì)胞新產(chǎn)品的先驅(qū)，致力于用作治療糖尿病、神經(jīng)系統(tǒng)疾病和血友病的產(chǎn)品。

LCT研發(fā)的DIABECELL?旨在使胰島素依賴型糖尿病患者的生活回歸正常，DIABECELL?在植入患者體內(nèi)后可有效地自我調(diào)節(jié)胰島素分泌。

應(yīng)用了LCT的包囊技術(shù)治療過程便無需使用免疫抑制藥物。

植入的細(xì)胞可使患者的血糖回歸接近正常水平，降低注射胰島素的需要并減少可能導(dǎo)致長期并發(fā)癥的高血糖癥，該項(xiàng)療法還旨在消除威脅生命的低血糖癥。

LCT在新西蘭開發(fā)了安全可靠的細(xì)胞來源，即生物認(rèn)證豬群，此外，公司還擁有通過藥品生產(chǎn)質(zhì)量管理規(guī)范（GMP）認(rèn)證的生產(chǎn)設(shè)施。公司與墨爾本、悉尼、奧克蘭、德國、意大利、俄羅斯和美國都有合作關(guān)系。

LCT is a cell implant company, incorporated in Australia with operations in New Zealand, that is focused on developing living cell products for the treatment of diabetes and neurological diseases.We have collaborations in Melbourne, Sydney, Auckland, Germany, Italy, Russia and the U.S. LCT is internationally recognised for its research and development of therapies in disease areas that typically have no cure or poor treatment options. Our most advanced therapy, DIABECELL? for Type 1 diabetes is in Phase IIb trials. The lives of more than 20 million people with Type 1 diabetes may well change as preliminary clinical trial information has shown that two patients with long standing insulin dependent diabetes did not require daily insulin injections after treatment with DIABECELL for a period of up to 32 weeks after treatment. The majority of patients treated to date with low initial doses have shown improvement of diabetes control with better glycated haemoglobin (%HbA1c) levels.

The ground-breaking early results with DIABECELL demonstrate that LCT is at the forefront of technological advancements both in cell bioprocessing and cell encapsulation with its proprietary biocompatible alginate.

LCT is listed on the Australian Securities Exchange (ASX:LCT) and the US-based OTCQX (OTCQX:LVCLY).